Morgan Stanley
LVTX

Morgan Stanley’s LAVA Therapeutics LVTX Stock Holding History

Morgan Stanley’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,600
Closed -$15.3K – 8282
2025
Q2 		$15.3K Sell
11,600
-200
-2% -$255 ﹤0.01% 6730
2025
Q1 		$15K Buy
11,800
+3,300
+39% +$3.67K ﹤0.01% 6665
2024
Q4 		$8.08K Sell
8,500
-27,900
-77% -$43.8K ﹤0.01% 6874
2024
Q3 		$60.4K Buy
36,400
+20,800
+133% +$38.1K ﹤0.01% 6159
2024
Q2 		$28.1K Buy
15,600
+5,400
+53% +$14.3K ﹤0.01% 6358
2024
Q1 		$34K Sell
10,200
-39,400
-79% -$86.7K ﹤0.01% 6348
2023
Q4 		$78.4K Buy
49,600
+39,300
+382% +$56.1K ﹤0.01% 6238
2023
Q3 		$15.1K Buy
10,300
+100
+1% +$179 ﹤0.01% 6571
2023
Q2 		$20.7K Buy
10,200
+1,300
+15% +$2.4K ﹤0.01% 6555
2023
Q1 		$14.8K Buy
8,900
+1,909
+27% +$5.34K ﹤0.01% 6737
2022
Q4 		$24.5K Buy
6,991
+1,991
+40% +$9.14K ﹤0.01% 6600
2022
Q3 		$23K Sell
5,000
-700
-12% -$1.93K ﹤0.01% 6733
2022
Q2 		$17K Buy
5,700
+2,900
+104% +$10.1K ﹤0.01% 7048
2022
Q1 		$12K Sell
2,800
-1,525
-35% -$7.75K ﹤0.01% 7350
2021
Q4 		$24K Buy
+4,325
New +$28.4K ﹤0.01% 7144

Other funds holding LVTX

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley's LVTX Position: Q3 2025 in Review

Morgan Stanley sold out of LAVA Therapeutics (LVTX) in Q3 2025, closing a stake of 11,600 shares — an estimated $15.3K sold.

Morgan Stanley first reported a position in LVTX in Q4 2021 and held it in 15 quarters. The position peaked at $78.4K in Q4 2023. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2025.

  • Morgan Stanley reported no remaining LAVA Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 11,600 LAVA Therapeutics shares in Q3 2025, an estimated $15.3K.
  • Morgan Stanley first reported a position in LAVA Therapeutics in Q4 2021 and held it in 15 quarters.
  • Morgan Stanley's LAVA Therapeutics position peaked at $78.4K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.